<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="publisher-id">PONE-D-11-06354</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0023185</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Immunology</subject>
            <subj-group>
              <subject>Immune cells</subject>
              <subject>Immune response</subject>
              <subject>Immunity</subject>
              <subject>Immunopathology</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Pulmonology</subject>
            <subj-group>
              <subject>Interstitial lung diseases</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Immunology</subject>
          <subject>Respiratory Medicine</subject>
        </subj-group>
      </article-categories><title-group><article-title>IL-1 and IL-23 Mediate Early IL-17A Production in Pulmonary Inflammation Leading to Late Fibrosis</article-title><alt-title alt-title-type="running-head">Lung Injury Depends on IL-17 and IL-23</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Gasse</surname>
            <given-names>Paméla</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Riteau</surname>
            <given-names>Nicolas</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Vacher</surname>
            <given-names>Rachel</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Michel</surname>
            <given-names>Marie-Laure</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Fautrel</surname>
            <given-names>Alain</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>di Padova</surname>
            <given-names>Franco</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Fick</surname>
            <given-names>Lizette</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Charron</surname>
            <given-names>Sabine</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Lagente</surname>
            <given-names>Vincent</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Eberl</surname>
            <given-names>Gérard</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Le Bert</surname>
            <given-names>Marc</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Quesniaux</surname>
            <given-names>Valérie F. J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Huaux</surname>
            <given-names>François</given-names>
          </name>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Leite-de-Moraes</surname>
            <given-names>Maria</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Ryffel</surname>
            <given-names>Bernhard</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Couillin</surname>
            <given-names>Isabelle</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff9">
            <sup>9</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1"><label>1</label><addr-line>University of Orleans and CNRS, UMR6218, Orleans, France</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>University of Paris V and CNRS, UMR8147, Paris, France</addr-line>       </aff><aff id="aff3"><label>3</label><addr-line>INSERM U991, Université de Rennes 1, Rennes, France</addr-line>       </aff><aff id="aff4"><label>4</label><addr-line>H2P2 Histopathological platform IFR140 INSERM U991, Université de Rennes 1, Rennes, France</addr-line>       </aff><aff id="aff5"><label>5</label><addr-line>Novartis Pharma, Basel, Switzerland</addr-line>       </aff><aff id="aff6"><label>6</label><addr-line>Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa</addr-line>       </aff><aff id="aff7"><label>7</label><addr-line>Institute Pasteur, Laboratory of Lymphoid Tissue Development, CNRS URA 1961, Paris, France</addr-line>       </aff><aff id="aff8"><label>8</label><addr-line>University Catholic of Louvain, Brussels, Belgium</addr-line>       </aff><aff id="aff9"><label>9</label><addr-line>Key-Obs S. A S., Orleans, France</addr-line>       </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Khader</surname>
            <given-names>Shabaana</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">University of Pittsburgh, United States of America</aff><author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">couillin@cnrs-orleans.fr</email></corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: IC ML-de-M BR FH GE VL FdiP. Performed the experiments: PG NR RV M-LM AF LF SC IC. Analyzed the data: IC ML-de-M PG NR AF LF VL MLB. Contributed reagents/materials/analysis tools: GE. Wrote the paper: IC VFJQ.</p>
        </fn>
      <fn fn-type="conflict">
        <p>Franco di Padova is a full-time employee of Novartis. The remaining authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="collection">
        <year>2011</year>
      </pub-date><pub-date pub-type="epub">
        <day>16</day>
        <month>8</month>
        <year>2011</year>
      </pub-date><volume>6</volume><issue>8</issue><elocation-id>e23185</elocation-id><history>
        <date date-type="received">
          <day>7</day>
          <month>4</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>7</month>
          <year>2011</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><copyright-holder>Gasse et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
        <sec>
          <title>Background</title>
          <p>Idiopathic pulmonary fibrosis is a devastating as yet untreatable disease. We demonstrated recently the predominant role of the NLRP3 inflammasome activation and IL-1β expression in the establishment of pulmonary inflammation and fibrosis in mice.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>The contribution of IL-23 or IL-17 in pulmonary inflammation and fibrosis was assessed using the bleomycin model in deficient mice.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>We show that bleomycin or IL-1β-induced lung injury leads to increased expression of early IL-23p19, and IL-17A or IL-17F expression. Early IL-23p19 and IL-17A, but not IL-17F, and IL-17RA signaling are required for inflammatory response to BLM as shown with gene deficient mice or mice treated with neutralizing antibodies. Using FACS analysis, we show a very early IL-17A and IL-17F expression by RORγt<sup>+</sup> γδ T cells and to a lesser extent by CD4αβ<sup>+</sup> T cells, but not by iNKT cells, 24 hrs after BLM administration. Moreover, IL-23p19 and IL-17A expressions or IL-17RA signaling are necessary to pulmonary TGF-β1 production, collagen deposition and evolution to fibrosis.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Our findings demonstrate the existence of an early IL-1β-IL-23-IL-17A axis leading to pulmonary inflammation and fibrosis and identify innate IL-23 and IL-17A as interesting drug targets for IL-1β driven lung pathology.</p>
        </sec>
      </abstract><funding-group><funding-statement>These authors have no support or funding to report.</funding-statement></funding-group><counts>
        <page-count count="12"/>
      </counts></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Idiopathic pulmonary fibrosis (IPF) represents a growing health issue, occurring from repeated lung injury of ill-defined origins. Patients suffering from this progressive form of interstitial lung disease present collagen accumulation and localised fibrotic foci in the absence of overt inflammation. Although chronic in nature, one complication is an accelerated phase of IPF. These exacerbations are characterized by acute inflammation reactivation which is frequently fatal within few weeks to a few months and underlining the important role of inflammation in IPF evolution <xref ref-type="bibr" rid="pone.0023185-Kondoh1">[1]</xref>. Using the murine model of bleomycin (BLM)-induced lung fibrosis, we previously showed that inflammation and fibrosis were mediated through the pro-inflammatory and pro-fibrotic cytokine IL-1beta (IL-1β) and IL-1R1/MyD88 signaling in resident cells <xref ref-type="bibr" rid="pone.0023185-Gasse1">[2]</xref> <xref ref-type="bibr" rid="pone.0023185-Gasse2">[3]</xref>. Since interleukin-17 (IL-17) is a major pro-inflammatory cytokine involved in neutrophil recruitment <xref ref-type="bibr" rid="pone.0023185-Ferretti1">[4]</xref>, <xref ref-type="bibr" rid="pone.0023185-Miyamoto1">[5]</xref> and chronic lung pathologies <xref ref-type="bibr" rid="pone.0023185-Braun1">[6]</xref>, <xref ref-type="bibr" rid="pone.0023185-Simonian1">[7]</xref>, we hypothesized that IL-1β secreted upon lung injury may induce innate “proTh17” IL-23 and IL-17 expression in lung resulting in pulmonary inflammation and evolution to fibrosis. Interestingly, a crucial role for IL-1 in the induction of IL-17-producing T cells that mediate autoimmune arthritis or EAE was reported, suggesting a link between IL-1 and IL-17 in establishment of some autoimmune diseases <xref ref-type="bibr" rid="pone.0023185-Nakae1">[8]</xref>, <xref ref-type="bibr" rid="pone.0023185-Sutton1">[9]</xref>. IL-1β and IL-23 were shown to induce innate IL-17 production from γδ T cells amplifying Th17 responses and autoimmunity <xref ref-type="bibr" rid="pone.0023185-Sutton2">[10]</xref>. More recently, a study showed that bleomycin and IL-1β-mediated pulmonary fibrosis was IL-17A dependent <xref ref-type="bibr" rid="pone.0023185-Wilson1">[11]</xref>. IL-17 was first described to be produced by a CD4<sup>+</sup>αβ T cell subset Th17, characterized by IL-17 (or IL-17A), but also IL-17F, IL-21, IL-22, IL-6 and TNF-α production <xref ref-type="bibr" rid="pone.0023185-Harrington1">[12]</xref>, <xref ref-type="bibr" rid="pone.0023185-Park1">[13]</xref>. The generation of CD4<sup>+</sup> Th17 subset is under the control of specific cytokines and transcription factors <xref ref-type="bibr" rid="pone.0023185-Weaver1">[14]</xref>. In mice, TGF-β is necessary and the switch to the Th17 pathway is induced by IL-6 and/or IL-21 <xref ref-type="bibr" rid="pone.0023185-Veldhoen1">[15]</xref> and requires IL-23 for full <italic>in vivo</italic> differentiation, expansion and migration into the circulation and peripheral tissues <xref ref-type="bibr" rid="pone.0023185-McGeachy1">[16]</xref>, <xref ref-type="bibr" rid="pone.0023185-Weaver2">[17]</xref>. Similar to IL-17A, IL-17F signals via a receptor complex composed with IL-17RA and IL-17RC. The relative contribution of IL-17A and F in lung fibrosis was still unknown. IL-17A was also shown to be produced very early by γδ T cells triggering protective immunity against infection <xref ref-type="bibr" rid="pone.0023185-Lockhart1">[18]</xref> exacerbating chronic inflammation <xref ref-type="bibr" rid="pone.0023185-Roark1">[19]</xref>. During an immune response, γδ T cells rapidly produce IL-17 in response to IL-23 and/or other dendritic cell products while antigen-specific CD4<sup>+</sup>αβ<sup>+</sup> Th17 cells develop later <xref ref-type="bibr" rid="pone.0023185-Stockinger1">[20]</xref>, <xref ref-type="bibr" rid="pone.0023185-Roark2">[21]</xref>. Recently NKT cells that lack the NK1.1 marker were also identified as early IL-17-producing cells that can contribute to neutrophil recruitment through IL-17 secretion <xref ref-type="bibr" rid="pone.0023185-Michel1">[22]</xref>. IL-17 synthesis depends on the RORγt transcription factor in both IL-17 producing CD4<sup>+</sup>αβ Th17 cells, and γδ T cells but also iNKT17 cells <xref ref-type="bibr" rid="pone.0023185-Ivanov1">[23]</xref>, <xref ref-type="bibr" rid="pone.0023185-Crossgrove1">[24]</xref>, <xref ref-type="bibr" rid="pone.0023185-Michel2">[25]</xref>.</p>
      <p>Here, we addressed the respective role of IL-17A and F, and the cellular source and activation cascade in response to BLM-induced airway injury. We show that lung injury triggers the expression of early IL-23, IL-17A and IL-17F in an IL-1 dependent manner, that early IL-23 and IL-17A, but not IL-17F are necessary for the establishment of the innate response to BLM and that γδ T cells are the major source of early IL-17A and IL-17F. Moreover, IL-23p19 is required for the late evolution to pulmonary fibrosis. Importantly, IL-23p19 and IL-17A are upstream of the expression of TGF-β1 the central mediator of lung fibrosis suggesting that innate IL-17A from γδ T cells <xref ref-type="bibr" rid="pone.0023185-Bonniaud1">[26]</xref> might promote the commitment towards an inflammatory Th17 phenotype through induction of TGF-β1 in an IL-6 rich environment.</p>
    </sec>
    <sec id="s2" sec-type="methods">
      <title>Methods</title>
      <sec id="s2a">
        <title>Mice</title>
        <p>IL-1R1−/− <xref ref-type="bibr" rid="pone.0023185-Glaccum1">[27]</xref>, IL-23/p19−/− <xref ref-type="bibr" rid="pone.0023185-Ghilardi1">[28]</xref> and IL-17RA−/− <xref ref-type="bibr" rid="pone.0023185-Ye1">[29]</xref> backcrossed 10 times on the wild-type C57BL/6 genetic background were bred in our animal facility at the Transgenose Institute (CNRS, Orleans). <italic>Rorc(</italic>γ<italic>t)-Gfp</italic><sup>TG</sup> were used for IL-17 producing cells investigation <xref ref-type="bibr" rid="pone.0023185-Sparwasser1">[30]</xref>. All animal experiments complied with the French Government's ethical and animal experiment regulations. This protocole was analysed and approved under the number CL2007-033 by the Ethic commitee for animal experimentation of CNRS and University in Orleans.</p>
      </sec>
      <sec id="s2b">
        <title>Treatments</title>
        <p>Bleomycin sulfate (5, 7.5 or 10 mg/kg) from Bellon Laboratories (Montrouge, France), rmIL-1β (50 µg/kg) from R&amp;D Systems (Minneapolis, USA) were given intranasally in 40 µL under light ketamine-xylasine anesthesia. IL-17A (100 µg, Novartis Pharma, Basel, Switzerland), IL-17F (100–150 µg, Dr C. Uyttenhove, Bruxelles, Bergium) neutralizing antibodies or control Ig were administered intranasally or intraperitonally. A dose-response study was performed to find the effective dose for both antibodies.</p>
      </sec>
      <sec id="s2c">
        <title>Bronchoalveolar Lavage Fluid (BALF)</title>
        <p>BALF was performed as previously described <xref ref-type="bibr" rid="pone.0023185-Gasse2">[3]</xref>.</p>
      </sec>
      <sec id="s2d">
        <title>Lung homogenization and analysis</title>
        <p>Lungs were homogenized and lung tissue myeloperoxidase activity (MPO) was evaluated as described <xref ref-type="bibr" rid="pone.0023185-Gasse2">[3]</xref>.</p>
      </sec>
      <sec id="s2e">
        <title>Cell count and determination</title>
        <p>Total cell and differential cell counts were determined in BALF as previously described <xref ref-type="bibr" rid="pone.0023185-Gasse2">[3]</xref>.</p>
      </sec>
      <sec id="s2f">
        <title>Mediator measurements by ELISA</title>
        <p>IL-1β, KC, IL-6 and TIMP-1 levels in BALF or lung homogenate were determined by ELISA (R&amp;D system, Minneapolis, USA). Latent or active TGF-β1 levels were assayed in BALF and lung homogenates by ELISA (R&amp;D, Minneapolis, USA). Latent or active TGFβ-1 was not detected in lung homogenates using this method.</p>
      </sec>
      <sec id="s2g">
        <title>Semi-quantitative PCR</title>
        <p>IL-17A, IL-17F, IL-23/p19 or IL-1β mRNA levels in lung were assessed (Online supplemented material). The electrophoresis gels were analyzed using a densitometric analyzer (ImageJ). Band densities were measured and compared to housekeeping gene HPRT1.</p>
      </sec>
      <sec id="s2h">
        <title>Zymographic analysis of MMPs</title>
        <p>MMP-2 activity was determined by gelatin zymography as described <xref ref-type="bibr" rid="pone.0023185-Gasse1">[2]</xref>.</p>
      </sec>
      <sec id="s2i">
        <title>Histology</title>
        <p>After BAL and lung perfusion, the large lobe was fixed and 3-µm sections were stained with Hematoxylin and Eosine (H&amp;E) or sirius red. For collagen determination the slides were stained with 0.1% picrosirius solution (0.1% sirius red in satured aqueous picric acid, pH 2) for 1 h, counterstained with Mayer's hematoxylin for 2 min. All the slides were numerised with Nikon i80 – X10 plan APO objective and QICAM color cooling camera (Qimaging). The lung sections were analyzed by imageJ - NIH software. The percentage of collagen was determined.</p>
      </sec>
      <sec id="s2j">
        <title>Total lung collagen assay</title>
        <p>Aliquots of lung homogenate (50 µl) were assayed for total lung collagen levels using the Sircol collagen dye binding assay according to the manufacturer's instructions (Biocolor Ltd, Northern Ireland).</p>
      </sec>
      <sec id="s2k">
        <title>Flow cytometry analysis</title>
        <p>Lung mononuclear cells were isolated and stimulated in the Online supplemented material. Cells were incubated with CD1d-tetramer-APC (NHI tetramer), anti-NK1.1-PerCP-Cy5.5, anti-CD4-APCalexa750, anti-CD8-PB, anti-TCRγδ-APC, anti-TCRαβ-APC, anti-CD11bPerCp Cy5.5 (BD PharMingen) or isotype control antibodies. For intracellular staining, cells were fixed with 4% PFA, washed, and permeabilized with 0.5% saponin (Sigma-Aldrich) in PBS, then incubated with anti-IL-17A-PE, anti-IL-17F-PE, anti-GFP alexa488, anti-IL12p40-FITC anti-IL-23p19-alexa647 or isotype controls. The cells were analyzed in a FACSCanto II (Becton Dickinson) by using FlowJo software.</p>
      </sec>
      <sec id="s2l">
        <title>Statistical Analysis</title>
        <p>Statistical evaluation of differences between the experimental groups was determined by non parametric one way analyse of variance test and Bonferroni post test using Prism software. <italic>P</italic> values of &lt;0.05 were considered statistically significant.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <sec id="s3a">
        <title>Early IL-23p19, IL-17A and IL-17F expression after airway bleomycin or IL-1β administration</title>
        <p>We previously showed that inflammation, remodeling and fibrosis after bleomycin (BLM) exposure were mediated through IL-1β release with recombinant murine IL-1β (rmIL-1β) recapitulating the effects of BLM <xref ref-type="bibr" rid="pone.0023185-Gasse1">[2]</xref>. We speculated that IL-1β secreted upon lung injury may induce innate IL-23 and IL-17 expression in lung resulting in pulmonary inflammation and evolution to fibrosis. Here we analyzed the expression of IL-23/p19 in the lung upon local BLM or rmIL-1β. Using semi-quantitative PCR analysis, we showed that IL-23/p19 mRNA expression is increased in lung of wild-type mice, 24 h after a single intranasal administration of BLM (<xref ref-type="fig" rid="pone-0023185-g001">Fig. 1A</xref>). Since IL-1β is induced following BLM, we asked whether rmIL-1β could also cause IL-23p19 expression. Indeed, instillation of rmIL-1β induced a significant increase of IL-23p19 pulmonary mRNA expression (<xref ref-type="fig" rid="pone-0023185-g001">Fig. 1A, B</xref>). Moreover BLM-induced pro-IL-1β expression in the lung was not affected in absence of IL-23p19 indicating that IL-1β is upstream of IL-23p19 (<xref ref-type="fig" rid="pone-0023185-g001">Fig. 1A, B</xref>). These results suggest that IL-1β produced locally upon lung injury induce IL-23p19 expression in the lung. Intracellular staining of IL-23p19<sup>+</sup> cells by flow cytometry confirmed that IL-23p19 is produced by lung infiltrating CD11b<sup>+</sup> monocytes (not shown). We then analyzed the respective expression of IL-17A and IL-17F in the lung after local BLM or rmIL-1β administration. We showed that IL-17A but not IL-17F mRNA expression is induced in the lung 24 h after BLM in these experimental conditions (<xref ref-type="fig" rid="pone-0023185-g001">Fig. 1C, D</xref>). Instillation of rmIL-1β induced a dramatic increase of IL-17A and IL-17F pulmonary mRNA expression (<xref ref-type="fig" rid="pone-0023185-g001">Fig. 1C, D</xref>). IL-17A and F expression after local BLM in IL-1R1 deficient mice was reduced in absence of IL-1R1 signaling suggesting that IL-1β produced locally upon lung injury may in turn induce IL-17A and IL-17F expression in the lung (<xref ref-type="fig" rid="pone-0023185-g001">Fig. 1C, D</xref>). These data show the existence of an IL-1β-IL-23-IL-17A axis following lung injury.</p>
        <fig id="pone-0023185-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0023185.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>IL-23p19, IL-17A or IL-17F expression upon BLM or rmIL-1β.</title>
            <p>mRNA expression for IL-23p19, Pro-IL-1β and HPRT1 in lung of 4 individual mice treated with BLM (10 mg/kg) or rmIL-1β (50 µg/kg) or saline were assessed using semi-quantitative PCR at 24 h in wild-type mice (A). Semi-quantitative IL-1β expression in the lung, evaluated with IL-1β/HPRT1 PCR ratio, was reduced in absence of IL-23p19 signaling (B). mRNA expression for IL-17A, IL-17F and HPRT1 in lung of 5 individual mice treated with BLM (10 mg/kg) or rmIL-1β (50 µg/kg) or saline wild-type mice or IL-1R1−/− mice were assessed using semi-quantitative PCR at 24 h (C). IL-17A and IL-17F mRNA levels were compared to the housekeeping gene HPRT1 mRNA levels and expressed as IL-17/HPRT ratio by measuring band densities using a densitometric analyzer (ImageJ) (D). Data represent in FiguremRNA expression Data represent mean values ± SD from 3 ratio independent experiments (n = 4 or 5 mice per group; *, <italic>p</italic>&lt;0.05; **, <italic>p</italic>&lt;0.01; ***, <italic>p</italic>&lt;0.001).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0023185.g001" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3b">
        <title>Early pulmonary inflammation is dependent on IL-23p19 and IL-17RA signaling</title>
        <p>To investigate whether IL-23p19 plays a role in lung inflammation upon lung injury, we evaluated early airway inflammatory cell response after airway BLM administration in lung of IL-23p19 deficient mice. Within 24 h, BLM elicited an acute neutrophil recruitment into the bronchoalveolar lavage fluid (BALF) and into the lung in C57BL/6 wild-type mice (<xref ref-type="fig" rid="pone-0023185-g002">Fig. 2A, B</xref>). In the absence of IL-23p19, neutrophil recruitment in the BALF (<xref ref-type="fig" rid="pone-0023185-g002">Fig. 2A</xref>) and neutrophil activity in the lung as assessed by MPO activity measurement (<xref ref-type="fig" rid="pone-0023185-g002">Fig. 2B</xref>) were dramatically reduced. Saline administration did not cause neutrophil influx in either group. IL-6 and KC production in lung 24 h after BLM were also diminished in the absence of IL-23p19 but IL-1β release was unaffected (not shown). To evaluate the role of IL-23p19 in the possible protease/antiprotease imbalance, we measured tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) levels into the lung after BLM administration. Production of TIMP-1 is the hallmark of evolution towards fibrosis. Twenty four hours after BLM administration, lung TIMP-1 was significantly increased in wild-type mice but not in IL-23p19 deficient mice (<xref ref-type="fig" rid="pone-0023185-g002">Fig. 2C</xref>). Thus, BLM induced airway neutrophil recruitment, KC, IL-6 and TIMP-1 expression in an IL-23p19 dependent way, while IL-1β release was likely upstream of IL-23. To assess whether innate IL-17A and/or IL-17F play a role in early lung inflammation, we evaluated the inflammatory cell response in the lung of mice deficient for IL-17 receptor (IL-17RA). In the absence of IL-17RA, neutrophil recruitment in the BALF (<xref ref-type="fig" rid="pone-0023185-g003">Fig. 3A</xref>) and neutrophil activity in lung (<xref ref-type="fig" rid="pone-0023185-g003">Fig. 3B</xref>) were dramatically reduced 24 h post BLM. Production of both KC (<xref ref-type="fig" rid="pone-0023185-g003">Fig. 3D</xref>) and IL-6 (<xref ref-type="fig" rid="pone-0023185-g003">Fig. 3E</xref>) in the lung were reduced in IL-17RA deficient mice but IL-1β levels were not significantly modified, indicating that IL-1β is upstream of IL-17 (<xref ref-type="fig" rid="pone-0023185-g003">Fig. 3C</xref>). Moreover 24 h after BLM administration, lung TIMP-1 expression was induced in wild-type mice but not in IL-17RA deficient mice (<xref ref-type="fig" rid="pone-0023185-g003">Fig. 3F</xref>). Thus, BLM induced airway neutrophil recruitment, KC, IL-6 and TIMP-1 expression in an IL-17RA dependent way, while IL-1β release was likely upstream of IL-17.</p>
        <fig id="pone-0023185-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0023185.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Acute inflammation and remodeling upon BLM are dependent on IL-23p19.</title>
            <p>Analysis of acute inflammation and remodeling was performed 24 h after BLM instillation (7.5 mg/kg). IL-23p19 deficient mice showed reduced neutrophil recruitment in BALF (A) and lung tissue (B) and reduced TIMP-1 production in lung (c) in comparison to wild-type mice Data represent mean values ± SD from 2 independent experiments (n = 5 mice per group; **, <italic>p</italic>&lt;0.01; ***, <italic>p</italic>&lt;0.001).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0023185.g002" xlink:type="simple"/>
        </fig>
        <fig id="pone-0023185-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0023185.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Impaired acute lung inflammation upon BLM in IL-17RA deficient mice.</title>
            <p>IL-17RA deficient mice showed reduced neutrophil recruitment in BALF (A) and lung tissue (B) in comparison to wild-type mice. BALs and myeloperoxidase (MPO) activity were performed 24 h after BLM instillation (7.5 mg/kg). KC (D), IL-6 (E) and TIMP-1 (F) levels in the lung were also reduced in IL-17RA deficient mice at 24 h but not IL-1β levels (C). Cytokines, chemokine and TIMP-1 quantification in lung homogenates were performed by ELISA. Data represent mean values ± SD from 4 independent experiments (n = 5 mice per group; ns, not significant, *, <italic>p</italic>&lt;0.05; **, <italic>p</italic>&lt;0.01).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0023185.g003" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3c">
        <title>IL-17A, but not IL-17F, is essential for bleomycin-induced acute lung inflammation and remodeling</title>
        <p>To determine the relative contribution of IL-17A and IL-17F in BLM-induced acute lung inflammation, we investigated the inflammatory response to BLM using neutralizing antibodies against IL-17A or IL-17F. Neutralization of IL-17A led to a significant reduction of neutrophil recruitment into the BALF (<xref ref-type="fig" rid="pone-0023185-g004">Fig. 4A</xref>) and reduction of neutrophil MPO activity in the lung (<xref ref-type="fig" rid="pone-0023185-g004">Fig. 4B</xref>) 24 h after BLM administration. IL-1β (<xref ref-type="fig" rid="pone-0023185-g004">Fig. 4C</xref>), KC (<xref ref-type="fig" rid="pone-0023185-g004">Fig. 4D</xref>), IL-6 (<xref ref-type="fig" rid="pone-0023185-g004">Fig. 4E</xref>) or TIMP-1 (<xref ref-type="fig" rid="pone-0023185-g004">Fig. 4F</xref>) lung levels were also reduced after IL-17A neutralization. Lower IL-1β in mice treated with anti-IL17A could be explained by the existence of an autocrine or paracrine loop with IL-17 inducing IL-1β production and amplifying the response. In contrast, we could exclude a role of IL-17F in these responses by analyzing the effect of IL-17F neutralizing antibodies. Blocking IL-17F had no significant effect on neutrophil recruitment into the BALF (<xref ref-type="fig" rid="pone-0023185-g005">Fig. 5A</xref>) or into the lung parenchyma as shown by MPO analysis (<xref ref-type="fig" rid="pone-0023185-g005">Fig. 5B</xref>). Pro-inflammatory cytokines and chemokine levels were also not reduced by IL-17F neutralizing antibodies (<xref ref-type="fig" rid="pone-0023185-g005">Fig. 5C–E</xref>). Moreover, anti-IL-17F antibodies had no effect on lung TIMP-1 levels (<xref ref-type="fig" rid="pone-0023185-g005">Fig. 5F</xref>). Anti-IL-17A and anti-IL-17F antibodies were used at doses efficient in blocking lung neutrophilic inflammation induced by intranasal administration of rmIL-17A or rmIL-17F, respectively, to C57BL/6 wild-type mice (data not shown). Therefore, locally BLM-induced inflammation, but also repair processes depend on functional IL-17A, but not on IL-17.</p>
        <fig id="pone-0023185-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0023185.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>Acute lung inflammation and remodeling upon BLM depends on IL-17A.</title>
            <p>Inflammatory and remodeling responses of wild-type mice treated with neutralizing antibody against IL-17A (150 µg/mouse, i.p. just after BLM or saline i.n. instillation). Neutrophil recruitment in BALF (A) and myeloperoxidase (MPO) activity in lung tissue (B) induced by BLM (7.5 mg/kg) were reduced after mice treatment with anti-IL-17A. IL-1β (C), KC (D), IL-6 (E) and TIMP-1 (F) levels in lung homogenates assessed by ELISA were also reduced 24 h after mice treatment neutralizing antibody against IL-17A. Data represent mean values ± SD from 3 independent experiments (n = 4 mice per group; *, <italic>p</italic>&lt;0.05; **, <italic>p</italic>&lt;0.01).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0023185.g004" xlink:type="simple"/>
        </fig>
        <fig id="pone-0023185-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0023185.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>Acute lung inflammation and remodeling upon BLM are independent of IL-17F.</title>
            <p>Inflammatory and remodeling responses upon BLM (7.5 mg/kg) of wild-type mice treated with neutralizing antibody against IL-17F (100–150 µg/mouse, i.p. just after BLM or saline i.n. instillation). Neutrophil recruitment in BALF (A) and myeloperoxidase (MPO) activity (B) upon BLM (7.5 mg/kg) were not reduced 24 h after treatment with high doses of neutralizing antibody against IL-17F. IL-1β (C), KC (D), IL-6 (E) and TIMP-1 (F) in lung homogenates assessed by ELISA were also reduced in BLM mice 24 h after treatment with neutralizing antibody against IL-17F. Treatments with anti-IL-17F had not significant effect on all these parameters. Data represent mean values ± SD from 2 independent experiments (n = 6 mice per group).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0023185.g005" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3d">
        <title>Cellular source of early IL-17A and F: γδ and αβ T cells but not iNKTcells</title>
        <p>In order to investigate the IL-17 producing cells in the lung in response to bleomycin administration, we used transgenic <italic>Rorc(γt)-Gfp</italic><sup>TG</sup> mice expressing EGFP under control of the <italic>Rorc(γt)</italic> promoter on a bacterial artificial chromosome (BAC) which allows visualization of the RORγt<sup>+</sup> cells <xref ref-type="bibr" rid="pone.0023185-Crossgrove1">[24]</xref>. RORγt was shown to be a marker for IL-17–producing cells in both αβ and γδ T cell populations <xref ref-type="bibr" rid="pone.0023185-Crossgrove1">[24]</xref>. Lymphocytes from the lung of <italic>Rorc(γt)-Gfp</italic><sup>TG</sup> mice were collected 24 h after BLM or saline administration, stimulated <italic>in vitro</italic> with PMA/ionomycin, and cell surface markers and intracellular staining for IL-17 were performed. FACS analysis showed that BLM administration enhanced the total number of IL-17A<sup>pos</sup>RORγt<sup>pos</sup> and IL-17F<sup>pos</sup>RORγt<sup>pos</sup> lung mononuclear cells (<xref ref-type="fig" rid="pone-0023185-g006">Fig. 6A</xref>). These IL-17-producing cells positive for RORγt were essentially γδ T cells and CD4<sup>pos</sup>αβ T cells but few iNKT cells (<xref ref-type="fig" rid="pone-0023185-g006">Fig. 6B</xref>). Up to 70% of IL-17A<sup>pos</sup>RORγt<sup>pos</sup> cells and 60% of IL-17F<sup>pos</sup>RORγt<sup>pos</sup> were γδ T cells. Among γδ T cells recruited after BLM administration, more than 30% produce IL-17A and 5% produce IL-17F (<xref ref-type="fig" rid="pone-0023185-g006">Fig. 6C</xref>). These data demonstrate that early IL-17A and F producing cells in response to BLM-induced lung injury are essentially γδ T cells and to a lesser extent CD4<sup>pos</sup>αβ T cells, while almost no iNKT cells produced IL-17A or F in these conditions.</p>
        <fig id="pone-0023185-g006" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0023185.g006</object-id>
          <label>Figure 6</label>
          <caption>
            <title>Early IL-17A and F are produced mainly by γδ T cells.</title>
            <p>Lymphocytes from the lung of <italic>Rorc(γt)-Gfp</italic><sup>TG</sup> mice were prepared 24 h after BLM or saline administration, and stimulated in vitro with PMA/ionomycin for 4 h. Specific staining of cell markers (CD1d-tetramer-APC, anti-NK1.1-PerCP-Cy5.5, anti-CD4-APCalexa750, anti-CD8-PB, anti-TCRγδ-APC, anti-TCRαβ-APC), or isotype control and intracellular staining for IL-17 (anti-IL-17A-PE, anti-IL-17F-PE, anti-GFP alexa488 or isotype controls) were performed. FACS analysis showed that BLM administration enhanced the total number of IL-17A<sup>pos</sup>RORγt<sup>pos</sup> and IL-17F<sup>pos</sup>RORγt<sup>pos</sup> lung mononuclear cells (A). IL-17-producing cells positive for RORγt were essentially γδ T cells and CD4<sup>pos</sup> αβ T cells but few iNKT cells (B). Among γδ T cells after bleomycin administration, at least 30% produce IL-17A and 5% produce IL-17F (C). Results are mean values ± SD from 4 independent experiments, with pools of 5 mice/group for each experiment, * p&lt;0.05; **, <italic>p</italic>&lt;0.01).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0023185.g006" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3e">
        <title>Lung remodeling and fibrosis are dependent on IL-23</title>
        <p>To further assesss the role of IL-23 in lung fibrosis we analyzed remodeling and fibrosis in lungs of IL-23p19 deficient mice 14 days after BLM administration. MMP-2 (or gelatinase A, 72 kDa) is well described in pulmonary fibrosis, preferentially secreted by fibroblasts and epithelial cells <xref ref-type="bibr" rid="pone.0023185-Suga1">[31]</xref>. Assessing gelatinase activity by zymography, we showed that BLM dramatically induced MMP-2 activity in wild-type mice and this activity was significantly reduced in IL-23p19 deficient mice (<xref ref-type="fig" rid="pone-0023185-g007">Fig. 7A</xref>). Moreover, BLM-induced TIMP-1 expression was also reduced in IL-23p19 deficient mice (<xref ref-type="fig" rid="pone-0023185-g007">Fig. 7B</xref>). Since TGF-β1 is essential in the development of lung fibrosis and also in the development of IL-17 producing cells in particular Th17 cells, we asked whether the production of TGF-β1 upon bleomycin is dependent on IL-23. Indeed, latent TGF-β1 was detected after activation in BALF from wild-type mice, 14 days after bleomycin administration but was reduced in BALF from IL-23p19 deficient (<xref ref-type="fig" rid="pone-0023185-g007">Fig. 7C</xref>). Active TGF-β1 was undetectable in BALF from wild-type and deficient mice probably due to lower production (data not shown). Microscopic analysis of lung sections showed extensive fibrotic areas with abundant collagen deposition as compared to normal alveolar structure of the saline controls 14 days post BLM. Cellular infiltrates, alveolar wall destruction and collagen deposition were significantly reduced in IL-17RA deficient mice (<xref ref-type="fig" rid="pone-0023185-g007">Fig. 7E</xref>) in comparison to BLM-treated wild-type mice. Collagen quantification in lung homogenates showed that total collagen content, enhanced 14 days after bleomycin instillation was significantly reduced in lung of IL-17RA deficient mice (<xref ref-type="fig" rid="pone-0023185-g007">Fig. 7D</xref>). These data demonstrate that lung remodeling and fibrosis require IL-23 for full responses <italic>in vivo</italic> and that IL-23 is involved in TGF-β1 production in response to epithelial lung injury induced by bleomycin.</p>
        <fig id="pone-0023185-g007" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0023185.g007</object-id>
          <label>Figure 7</label>
          <caption>
            <title>Remodeling and fibrosis are dependent on IL-23p19.</title>
            <p>Analysis of late pulmonary remodeling and fibrosis was performed 14 days after BLM administration (5 mg/kg). MMP-2 activity (A) and TIMP-1 production (B) were reduced in IL-23p19 deficient mice. Active MMP-2 was expressed as relative intensity (RI). Latent TGF-β1 detected in BALF from wild-type mice was reduced in BALF from IL-23p19 deficient mice (C). Total collagen content in lung was significantly reduced in IL-23p19 deficient mice in comparision to wild-type mice (D). Collagen was measured using the Sircol collagen dye binding assay. Lung microscopic sections showed extensive fibrotic areas with collagen deposition in wild-type mice treated with BLM which was attenuated in IL-23p19−/− mice (e). Sirius red (SR) staining, scale bars 1 mm and 200 µm, n = 5 mice. Data represent mean values ± SD from 2 independent experiments (n = 5 mice per group; *, <italic>p</italic>&lt;0.05; **, <italic>p</italic>&lt;0.01; ***, <italic>p</italic>&lt;0.001).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0023185.g007" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3f">
        <title>Bleomycin-induced remodeling, lung fibrosis and TGF-β1 are reduced in the absence of IL-17RA signaling and can be prevented by IL-17A neutralization</title>
        <p>Furthermore, the analysis of remodeling in lung of IL-17RA deficient mice 14 days after BLM administration showed that MMP-2 activity and TIMP-1 level were reduced (<xref ref-type="fig" rid="pone-0023185-g008">Fig. 8A, B</xref>). As latent TGF-β1 was reduced in BALF from IL-23-p19 deficient mice, we asked whether it required functional IL-17A. Latent TGF-β1 expression was also reduced in IL-17RA deficient mice (<xref ref-type="fig" rid="pone-0023185-g008">Fig. 8C</xref>) whereas active TGF-β1 remained undetectable (data not shown). Total collagen content in lung was significantly reduced in IL-17RA deficient mice in comparision to wild-type mice (<xref ref-type="fig" rid="pone-0023185-g008">Fig. 8D</xref>). Moreover, we observed that cellular infiltrates, alveolar wall destruction and collagen deposition were significantly reduced in IL-17RA deficient (<xref ref-type="fig" rid="pone-0023185-g008">Fig. 8E</xref>) in comparison to BLM-treated wild-type mice.</p>
        <fig id="pone-0023185-g008" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0023185.g008</object-id>
          <label>Figure 8</label>
          <caption>
            <title>Attenuation of bleomycin-induced lung fibrosis in IL-17RA−/− mice.</title>
            <p>Pulmonary remodeling and fibrotic response of wild-type mice or IL-17RA deficient mice 14 days after BLM or saline i.n. instillation. MMP-2 (72 Kd) activity in BALF was analyzed by zymography 14 days after administration of BLM (5 mg/kg i.n.). Active MMP-2 was upregulated at day 14 after BLM in the BALF of wild-type mice but only partially in IL-17RA−/− mice (A). TIMP-1 as indicator of a fibrotic process was upregulated in the lungs of B6, but to a lesser extent in IL-17RA−/− mice on day 14 (B). The latent form of TGF-β1 was present in BALF from B6 mice, 14 days after BLM, but was reduced in BALF from IL-17RA deficient mice as determined by ELISA assay (C). Active MMP-2 was expressed as relative intensity (RI). TIMP-1 and TGF-β1 levels were assessed by ELISA. Total collagen content enhanced 14 days after bleomycin instillation was significantly reduced in lung of IL-17RA deficient mice (D). Collagen was measured using the Sircol collagen dye binding assay. Data represent mean values ± SD from 2 independent experiments (n = 4 mice per group; *, <italic>p</italic>&lt;0.05; **, <italic>p</italic>&lt;0.01; ***<italic>p</italic>&lt;0.001). Lung microscopic sections showed extensive fibrotic areas at day 14 with collagen deposition in wild-type mice treated with BLM (5 mg/kg i.n.) which was attenuated in IL-17RA−/− mice (E). Sirius red (SR) staining, scale bars 1 mm and 200 µm, n = 5 mice).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0023185.g008" xlink:type="simple"/>
        </fig>
        <p>We further confirmed the implication of IL-17A in lung remodeling, and demonstrate that these developments can be prevented by anti-IL-17A neutralizing antibodies. Antibodies to IL-17A administered after BLM reduced MMP-2 activity in BALF (<xref ref-type="fig" rid="pone-0023185-g009">Fig. 9A</xref>), TIMP-1 level in lung (<xref ref-type="fig" rid="pone-0023185-g009">Fig. 9B</xref>) and latent TGF-β1 level in BALF (<xref ref-type="fig" rid="pone-0023185-g009">Fig. 9C</xref>) in wild-type mice. Moreover, anti-IL-17A antibody treatment attenuated pulmonary fibrosis observed at day 14 (<xref ref-type="fig" rid="pone-0023185-g009">Fig. 9E</xref>). Remodeling response, analyzed by collagen specific sirius red staining of microscopic lung sections showed that lung collagen content, enhanced after BLM, was significantly reduced by anti-IL-17A antibody treatment (<xref ref-type="fig" rid="pone-0023185-g009">Fig. 9D</xref>). Therefore, IL-17A and IL-17RA signaling are required for the development of pulmonary inflammation, fibrosis, and collagen deposition in response to bleomycin and IL-17A neutralization can prevent evolution towards fibrosis.</p>
        <fig id="pone-0023185-g009" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0023185.g009</object-id>
          <label>Figure 9</label>
          <caption>
            <title>Attenuation of bleomycin-induced lung fibrosis upon anti-IL-17A treatment.</title>
            <p>Pulmonary remodeling and fibrotic responses of wild-type mice treated with neutralizing antibody against IL-17A (150 µg/mouse, i.p. just after BLM and 3 times per week) 14 days after BLM (5 mg/kg i.n.) or saline. MMP-2 (72 Kd) activity in BALF was analyzed by zymography 14 days after administration of BLM. Active MMP-2 upregulated upon BLM in the BALF of wild-type mice was greatly reduced after 6 treatments with neutralizing antibody against IL-17A (A). TIMP-1 in lung was also significantly decreased after treatment with neutralizing antibody against IL-17A in comparison to untreated BLM mice (B). Latent TGF-β1 detected in BALF from wild-type mice was reduced in BALF from wild-type mice treated with anti-IL-17A antibodies (C). Active MMP-2 was expressed as relative intensity (RI). TIMP-1 and TGF-β1 levels were assessed by ELISA. In order to quantify lung collagen deposition, all the slides were numerised by Qimaging and analyzed by imageJ - NIH software. % of SR by lung were shown. Collagen content enhanced after BLM was significantly reduced when the mice were treated with anti-IL-17A antibody (D). Data represent mean values ± SD from 2 independent experiments (n = 5 mice per group; *, <italic>p</italic>&lt;0.05; ***, <italic>p</italic>&lt;0.001). Lung microscopic sections showed extensive fibrotic areas at day 14 with collagen deposition in wild-type mice administrated with BLM which was attenuated in mice treated with neutralizing antibodies against IL-17A (E). Sirius red (SR) staining, scale bars 1 mm and 200 µm, n = 5 mice.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0023185.g009" xlink:type="simple"/>
        </fig>
      </sec>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>In this study, we report the involvement of IL-23p19 and innate IL-17A in the occurrence of pulmonary inflammation and fibrosis and demonstrate the critical role of IL-1β in these processes. We show the existence of an IL-1β/IL-23/IL-17 axis which is essential for bleomycin-induced pulmonary inflammation, remodeling and fibrosis. While this study was being finalized, Wilson and colleagues published a study reporting a critical role for IL-17A in BLM- or IL-1β-induced lung fibrosis <xref ref-type="bibr" rid="pone.0023185-Wilson1">[11]</xref>.</p>
      <p>IL-23p19 and IL-17A were expressed early in tissue following local bleomycin suggesting that these cytokines play a role in lung injury-induced inflammation and subsequent evolution to fibrosis. Wilson et al showed a weak IL-17A protein expression after restimulation of BAL and lung cells at day 4 and day 7 post BLM administration, respectively followed by a high IL-17A expression on day 7, 14 and 21 after bleomycin <xref ref-type="bibr" rid="pone.0023185-Wilson1">[11]</xref>. We previously outlined that exogenous IL-1β can mimic the BLM-induced pathology <xref ref-type="bibr" rid="pone.0023185-Gasse1">[2]</xref> and this was confirmed by Wilson et al <xref ref-type="bibr" rid="pone.0023185-Wilson1">[11]</xref>. We analyzed the effect of airway rmIL-1β on pulmonary IL-23p19 and IL-17 expression. IL-23p19, IL-17A and IL-17F mRNA were strongly increased after airway rmIL-1β administration and bleomycin-induced IL-17A and IL-17F expression were dependent on IL-1R1 signaling, demonstrating that IL-1β is upstream of IL-17. Further, IL-17 may promote IL-1β production by an amplification loop. Therefore the data suggest that lung injury promotes IL-1β production which increases IL-23 expression and in turn can stimulate innate IL-17 expression. An IL-1β/IL-17 axis has been reported in experimental autoimmune encephalomyelitis and arthritis for which a crucial role for IL-1β in the induction of IL-17-producing T cells was demonstrated <xref ref-type="bibr" rid="pone.0023185-Sutton1">[9]</xref>, <xref ref-type="bibr" rid="pone.0023185-Sutton2">[10]</xref>, <xref ref-type="bibr" rid="pone.0023185-Nakae2">[32]</xref>. Moreover IL-1β drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist (IL-1Ra)-deficient <xref ref-type="bibr" rid="pone.0023185-Koenders1">[33]</xref>. Chronic destructive arthritis was reduced in IL-17RA deficient mice whereas abolished in IL-1R1 deficient mice <xref ref-type="bibr" rid="pone.0023185-Joosten1">[34]</xref>. In multiple sclerosis, IL-17 was produced by microglia in response to IL-23 or IL-1β <xref ref-type="bibr" rid="pone.0023185-Kawanokuchi1">[35]</xref>. In mice, IL-1β and IL-23 are produced by dendritic cells upon infection-induced Th-17 cells <xref ref-type="bibr" rid="pone.0023185-Shainheit1">[36]</xref>. After lung injury, IL-1β may be produced very early by dendritic cells and alveolar macrophages acting on IL-17 producing cells to promote IL-17 expression. Our study showed for the first time that early IL-23p19 and IL-17RA signaling were necessary to trigger pulmonary inflammation and remodeling responses in response to lung injury. We confirmed the role of IL-17A in these responses <xref ref-type="bibr" rid="pone.0023185-Wilson1">[11]</xref>. Furthermore, we document the relative role of IL-17A versus IL-17F in lung inflammation leading to fibrosis, an aspect not known before <xref ref-type="bibr" rid="pone.0023185-Ishigame1">[37]</xref>. We showed that IL-17A promotes pulmonary inflammation and remodeling upon airway BLM whereas IL-17F has no effect. IL-17A and IL-17F which are highly homologous members of the IL-17 protein family and bind the same receptor complex consisting of IL-17RA and IL-17RC were often described as pro-inflammatory cytokines with redundant role in inflammation and autoimmunity. IL-17F apparently plays a marginal role in the development of delayed-type and contact hypersensitivities, autoimmune encephalomyelitis, collagen-induced arthritis, and arthritis in IL-1Ra deficient mice. In asthma, IL-17F may play an important regulatory role and seems to function differently than IL-17A <xref ref-type="bibr" rid="pone.0023185-Ishigame1">[37]</xref>, <xref ref-type="bibr" rid="pone.0023185-Yang1">[38]</xref>. Our results suggest that unlike IL-17A, IL-17F has no essential role in acute inflammation in our model. Overlapping or distinct roles of these cytokines may depend on IL-17A and/or IL-17F production by different cell types or on the role of functional homodimers or heterodimers. Since the role of innate IL-17 is less known and in an attempt to identify the cells producing IL-17 very early, we found γδ T cells but neither iNKT cells nor αβ T cells as the major source of innate IL-17A and IL-17F, 24 hrs after induction of lung injury. IL-17-producing γδ T cell were present in naïve mice and enhanced after bleomycin. Indeed, IL-17- producing γδ T cells may be differentiated in the periphery and poised ready to produce IL-17 in a rapid manner <xref ref-type="bibr" rid="pone.0023185-Shibata1">[39]</xref>. This is the first demonstration of early IL-17A and F production by γδ T cell after pulmonary injury. IL-17A producing γδ T cells are more present than IL-17F producing γδ T cells in agreement with the predominant role of IL-17A in pulmonary inflammation after injury. Late pulmonary induction of IL-17 expression by γδ T cells 7 and 14 days after local bleomycin was reported but the direct role of the IL-17 on late inflammation and fibrosis was not studied <xref ref-type="bibr" rid="pone.0023185-Braun1">[6]</xref>. Moreover, in this study deletion of all γδ T cell was associated with reduced inflammation in the bronchoalveolar space but severe interstitial inflammation with complete loss of alveolar structure and delayed epithelium repair 7 and 14 days after bleomycin. By contrast, using mice deficient for IL-17 signaling or treated with anti-IL-17 antibodies, we show reduced inflammation in the bronchoalveolar space and in interstitium inflammation and confirmed two studies reporting that IL-17 has a detrimental role in lung fibrosis <xref ref-type="bibr" rid="pone.0023185-Braun1">[6]</xref>, <xref ref-type="bibr" rid="pone.0023185-Wilson1">[11]</xref>. Dendritic epidermal γδ T cells involved in skin epithelium wound repair <xref ref-type="bibr" rid="pone.0023185-Jameson1">[40]</xref> may also contribute to lung epithelium repair as suggested in the lung of tobacco smokers without COPD <xref ref-type="bibr" rid="pone.0023185-Pons1">[41]</xref>. Depletion of these cells might be responsible for the disease aggravation described in γδ deficient mice <xref ref-type="bibr" rid="pone.0023185-Braun1">[6]</xref>. Dendritic epidermal γδ T cells with lung wound repair activity and IL-17 producing γδ T cells with detrimental effect may coexist in the airways after lung injury. This could explain the different phenotypes observed between our study with mice deficient for IL-17 signaling and Braun and collagues's study with mice deficient for γδ T cells. As we show that early IL-17 producing cells are essentially γδ T cells, this suggests that IL-17 producing γδ T cells have a detrimental effect probably in inducing the expansion of Th17 which are auto-reactive and pathogenic T cells. γδ T cells were described as non-conventional T-cell implicated in early innate immunity whereas conventional CD4 αβ Th17 cells were often involved in adaptive immunity suggesting that late IL-17 producing cells in response to bleomycin-induced lung damages would be CD4 αβ Th17 cells <xref ref-type="bibr" rid="pone.0023185-Roark2">[21]</xref>. In support of this, it was shown that IL-17-producing γδ T cells activated by IL-1β and IL-23 can promote IL-17 production by CD4<sup>+</sup> T cells suggesting that γδ T cells act in an amplification loop for IL-17 production by Th17 cells <xref ref-type="bibr" rid="pone.0023185-Sutton2">[10]</xref>. Even if IL-17 production by γδ T cells has a protective role in inducing adaptive immune response against infection, IL-17 producing γδ T cells were implicated in inflammatory diseases associated with tissue damage <xref ref-type="bibr" rid="pone.0023185-Ito1">[42]</xref>, <xref ref-type="bibr" rid="pone.0023185-Shichita1">[43]</xref> and in the generation and activation of IL-17-producing auto-reactive T cells. IL-17-producing γδ T cells exacerbate collagen-induced arthritis and experimental autoimmune encephalomyelitis (EAE) <xref ref-type="bibr" rid="pone.0023185-Sutton2">[10]</xref>.</p>
      <p>Interestingly we report that airway TGF-β1, the main critical mediator of remodeling and fibrotic responses in the lung, was induced after lung injury in wild-type mice but strongly reduced in IL-23p19 and IL-17RA deficient mice or wild-type mice treated with anti-IL-17A antibodies indicating that IL-23p19 and IL-17A are upstream of the expression of TGF-β1 and suggesting that innate IL-17A produced by γδ T lymphocytes may influence the production of TGF-β1. In case of repeated injury, the emergence of TGF-β1 as a component associated with cellular injury and inflammation with IL-6 and IL-1β would provide the conditions for differentiation of CD4 αβ Th17 cells as a second wave of immune response. Wilson et al reported that IL-17A-induced fibrosis depend on TGF-β1. This may be explained by the existence of an amplification loop, early IL-17A inducing TGF-β1 and TGF-β1-dependent production of late IL-17A. Moreover, we showed for the first time that IL-23 is required for full establishment of pulmonary inflammation, remodeling and fibrosis in mice. IL-12p40 subunit, which associates with IL-23p19 subunit to form IL-23 cytokine, but neither IL-12p35 nor IL-12p70, was shown to play a key role in silica-induced pulmonary inflammation and fibrosis <xref ref-type="bibr" rid="pone.0023185-Huaux1">[44]</xref>. Increased serum IL-23 was observed in patients with systemic sclerosis <xref ref-type="bibr" rid="pone.0023185-Komura1">[45]</xref>. Our results strongly support the notion that IL-23 is required for IL-17 production by γδ T cells in response to epithelial cell damage. Naïve γδ T cells have been shown to produce IL-17 in response to IL-23 alone <xref ref-type="bibr" rid="pone.0023185-Lockhart1">[18]</xref>, <xref ref-type="bibr" rid="pone.0023185-Shibata1">[39]</xref> and to constitutively express IL-23 receptor <xref ref-type="bibr" rid="pone.0023185-Sutton2">[10]</xref>, <xref ref-type="bibr" rid="pone.0023185-Martin1">[46]</xref>. These cells have a pathogenic role in severe disease such as collagen-induced arthritis <xref ref-type="bibr" rid="pone.0023185-Roark1">[19]</xref>. In this case they appear to be driven by self molecules that arise during inflammation. Such a break of self tolerance with induction of pathogenic IL-17 producing γδ T cells should be possible in the case of repeated lung injury and inflammation leading to pulmonary fibrosis. Our study showed for the first time that IL-23p19 and IL-17RA signaling were necessary to trigger late pulmonary inflammation and fibrosis and confirmed by IL-17A neutralization that IL-17A is required for late disease <xref ref-type="bibr" rid="pone.0023185-Wilson1">[11]</xref>. Wilson's study and our work are largely in agreement or complementary although minor discrepancies may be due to the use of two different sources of bleomycin <xref ref-type="bibr" rid="pone.0023185-Wilson1">[11]</xref>. Another study described how IL-17A may regulate the expression and/or proinflammatory properties of IL-22 in pulmonary fibrosis but did bot analysed the link between IL-1β, IL-23and IL-17 <xref ref-type="bibr" rid="pone.0023185-Sonnenberg1">[47]</xref>.</p>
      <p>In conclusion, we highlighted the existence of an innate IL-1β-IL-23-IL-17A axis in the establishment of early pulmonary inflammation with direct consequences on late evolution to fibrosis after lung injury. We demonstrate that IL-23p19, IL-17A and IL-17RA signaling are essential to pulmonary inflammation whereas IL-17F seems dispensable. Moreover we identified γδ T cells as the major source of early IL-17A, providing a new mechanism whereby IL-1 and IL-23 may mediate pulmonary fibrosis. IL-23p19 was identified for the first time as an essential mediator of pulmonary fibrosis. Importantly, IL-23p19 and IL-17A are upstream of TGF-β1 the central mediator of lung fibrosis. Our findings point on the potential role of IL-17-producing TCRγδ T cells in lung injury as a first line of defense that can orchestrate an inflammatory response leading to pulmonary fibrosis. Our study provides new information on the pathogenic role of IL-23 and IL-17 underlining the importance of targeting these cytokines in the development of new therapeutic approaches against lung fibrosis.</p>
    </sec>
    <sec id="s5">
      <title>Supporting Information</title>
      <supplementary-material id="pone.0023185.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0023185.s001" xlink:type="simple">
        <label>Methods S1</label>
        <caption>
          <p>The methods for semi-quantitative PCR and flow cytometry.</p>
          <p>(DOCX)</p>
        </caption>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>We acknowledge the skilled technical assistance of Louis Fauconnier (UMR6218 IEM, Orleans), and Isabelle Guenon (INSERM U620, Université de Rennes 1). We acknowledge Dr C. Uyttenhove for the kind gift of IL-17A and IL-17F neutralizing antibodies and Dr J. Van Snick for the gift of IL-23 antibodies (Ludwig Institute for Cancer Research, Brussels). The authors are grateful to François Erard for scientific discussion and correction of the manuscript.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pone.0023185-Kondoh1">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kondoh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Taniguchi</surname><given-names>H</given-names></name><name name-style="western"><surname>Kawabata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yokoi</surname><given-names>T</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name><etal/></person-group>             <year>1993</year>             <article-title>Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases.</article-title>             <source>Chest</source>             <volume>103</volume>             <fpage>1808</fpage>             <lpage>1812</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Gasse1">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gasse</surname><given-names>P</given-names></name><name name-style="western"><surname>Mary</surname><given-names>C</given-names></name><name name-style="western"><surname>Guenon</surname><given-names>I</given-names></name><name name-style="western"><surname>Noulin</surname><given-names>N</given-names></name><name name-style="western"><surname>Charron</surname><given-names>S</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice.</article-title>             <source>J Clin Invest</source>             <volume>117</volume>             <fpage>3786</fpage>             <lpage>3799</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Gasse2">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gasse</surname><given-names>P</given-names></name><name name-style="western"><surname>Riteau</surname><given-names>N</given-names></name><name name-style="western"><surname>Charron</surname><given-names>S</given-names></name><name name-style="western"><surname>Girre</surname><given-names>S</given-names></name><name name-style="western"><surname>Fick</surname><given-names>L</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis.</article-title>             <source>Am J Respir Crit Care Med</source>             <volume>179</volume>             <fpage>903</fpage>             <lpage>913</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Ferretti1">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ferretti</surname><given-names>S</given-names></name><name name-style="western"><surname>Bonneau</surname><given-names>O</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>GR</given-names></name><name name-style="western"><surname>Jones</surname><given-names>CE</given-names></name><name name-style="western"><surname>Trifilieff</surname><given-names>A</given-names></name></person-group>             <year>2003</year>             <article-title>IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger.</article-title>             <source>J Immunol</source>             <volume>170</volume>             <fpage>2106</fpage>             <lpage>2112</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Miyamoto1">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Miyamoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Prause</surname><given-names>O</given-names></name><name name-style="western"><surname>Sjostrand</surname><given-names>M</given-names></name><name name-style="western"><surname>Laan</surname><given-names>M</given-names></name><name name-style="western"><surname>Lotvall</surname><given-names>J</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways.</article-title>             <source>J Immunol</source>             <volume>170</volume>             <fpage>4665</fpage>             <lpage>4672</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Braun1">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>RK</given-names></name><name name-style="western"><surname>Ferrick</surname><given-names>C</given-names></name><name name-style="western"><surname>Neubauer</surname><given-names>P</given-names></name><name name-style="western"><surname>Sjoding</surname><given-names>M</given-names></name><name name-style="western"><surname>Sterner-Kock</surname><given-names>A</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>IL-17 producing gammadelta T cells are required for a controlled inflammatory response after bleomycin-induced lung injury.</article-title>             <source>Inflammation</source>             <volume>31</volume>             <fpage>167</fpage>             <lpage>179</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Simonian1">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Simonian</surname><given-names>PL</given-names></name><name name-style="western"><surname>Roark</surname><given-names>CL</given-names></name><name name-style="western"><surname>Wehrmann</surname><given-names>F</given-names></name><name name-style="western"><surname>Lanham</surname><given-names>AK</given-names></name><name name-style="western"><surname>Diaz del Valle</surname><given-names>F</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis.</article-title>             <source>J Immunol</source>             <volume>182</volume>             <fpage>657</fpage>             <lpage>665</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Nakae1">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Nakae</surname><given-names>S</given-names></name><name name-style="western"><surname>Saijo</surname><given-names>S</given-names></name><name name-style="western"><surname>Horai</surname><given-names>R</given-names></name><name name-style="western"><surname>Sudo</surname><given-names>K</given-names></name><name name-style="western"><surname>Mori</surname><given-names>S</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>100</volume>             <fpage>5986</fpage>             <lpage>5990</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Sutton1">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sutton</surname><given-names>C</given-names></name><name name-style="western"><surname>Brereton</surname><given-names>C</given-names></name><name name-style="western"><surname>Keogh</surname><given-names>B</given-names></name><name name-style="western"><surname>Mills</surname><given-names>KH</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>EC</given-names></name></person-group>             <year>2006</year>             <article-title>A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis.</article-title>             <source>J Exp Med</source>             <volume>203</volume>             <fpage>1685</fpage>             <lpage>1691</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Sutton2">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sutton</surname><given-names>CE</given-names></name><name name-style="western"><surname>Lalor</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>CM</given-names></name><name name-style="western"><surname>Brereton</surname><given-names>CF</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>EC</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity.</article-title>             <source>Immunity</source>             <volume>31</volume>             <fpage>331</fpage>             <lpage>341</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Wilson1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>MS</given-names></name><name name-style="western"><surname>Madala</surname><given-names>SK</given-names></name><name name-style="western"><surname>Ramalingam</surname><given-names>TR</given-names></name><name name-style="western"><surname>Gochuico</surname><given-names>BR</given-names></name><name name-style="western"><surname>Rosas</surname><given-names>IO</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent.</article-title>             <source>J Exp Med</source>             <volume>207</volume>             <fpage>535</fpage>             <lpage>552</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Harrington1">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Harrington</surname><given-names>LE</given-names></name><name name-style="western"><surname>Hatton</surname><given-names>RD</given-names></name><name name-style="western"><surname>Mangan</surname><given-names>PR</given-names></name><name name-style="western"><surname>Turner</surname><given-names>H</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>TL</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.</article-title>             <source>Nat Immunol</source>             <volume>6</volume>             <fpage>1123</fpage>             <lpage>1132</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Park1">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>XO</given-names></name><name name-style="western"><surname>Chang</surname><given-names>SH</given-names></name><name name-style="western"><surname>Nurieva</surname><given-names>R</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.</article-title>             <source>Nat Immunol</source>             <volume>6</volume>             <fpage>1133</fpage>             <lpage>1141</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Weaver1">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Weaver</surname><given-names>CT</given-names></name><name name-style="western"><surname>Hatton</surname><given-names>RD</given-names></name><name name-style="western"><surname>Mangan</surname><given-names>PR</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>LE</given-names></name></person-group>             <year>2007</year>             <article-title>IL-17 family cytokines and the expanding diversity of effector T cell lineages.</article-title>             <source>Annu Rev Immunol</source>             <volume>25</volume>             <fpage>821</fpage>             <lpage>852</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Veldhoen1">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Veldhoen</surname><given-names>M</given-names></name><name name-style="western"><surname>Hocking</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Locksley</surname><given-names>RM</given-names></name><name name-style="western"><surname>Stockinger</surname><given-names>B</given-names></name></person-group>             <year>2006</year>             <article-title>TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.</article-title>             <source>Immunity</source>             <volume>24</volume>             <fpage>179</fpage>             <lpage>189</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-McGeachy1">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>McGeachy</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tato</surname><given-names>CM</given-names></name><name name-style="western"><surname>Laurence</surname><given-names>A</given-names></name><name name-style="western"><surname>Joyce-Shaikh</surname><given-names>B</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo.</article-title>             <source>Nat Immunol</source>             <volume>10</volume>             <fpage>314</fpage>             <lpage>324</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Weaver2">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Weaver</surname><given-names>CT</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>LE</given-names></name><name name-style="western"><surname>Mangan</surname><given-names>PR</given-names></name><name name-style="western"><surname>Gavrieli</surname><given-names>M</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>KM</given-names></name></person-group>             <year>2006</year>             <article-title>Th17: an effector CD4 T cell lineage with regulatory T cell ties.</article-title>             <source>Immunity</source>             <volume>24</volume>             <fpage>677</fpage>             <lpage>688</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Lockhart1">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lockhart</surname><given-names>E</given-names></name><name name-style="western"><surname>Green</surname><given-names>AM</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>JL</given-names></name></person-group>             <year>2006</year>             <article-title>IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection.</article-title>             <source>J Immunol</source>             <volume>177</volume>             <fpage>4662</fpage>             <lpage>4669</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Roark1">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Roark</surname><given-names>CL</given-names></name><name name-style="western"><surname>French</surname><given-names>JD</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>MA</given-names></name><name name-style="western"><surname>Bendele</surname><given-names>AM</given-names></name><name name-style="western"><surname>Born</surname><given-names>WK</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Exacerbation of collagen-induced arthritis by oligoclonal, IL-17-producing gamma delta T cells.</article-title>             <source>J Immunol</source>             <volume>179</volume>             <fpage>5576</fpage>             <lpage>5583</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Stockinger1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Stockinger</surname><given-names>B</given-names></name><name name-style="western"><surname>Veldhoen</surname><given-names>M</given-names></name><name name-style="western"><surname>Martin</surname><given-names>B</given-names></name></person-group>             <year>2007</year>             <article-title>Th17 T cells: linking innate and adaptive immunity.</article-title>             <source>Semin Immunol</source>             <volume>19</volume>             <fpage>353</fpage>             <lpage>361</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Roark2">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Roark</surname><given-names>CL</given-names></name><name name-style="western"><surname>Simonian</surname><given-names>PL</given-names></name><name name-style="western"><surname>Fontenot</surname><given-names>AP</given-names></name><name name-style="western"><surname>Born</surname><given-names>WK</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>RL</given-names></name></person-group>             <year>2008</year>             <article-title>gammadelta T cells: an important source of IL-17.</article-title>             <source>Curr Opin Immunol</source>             <volume>20</volume>             <fpage>353</fpage>             <lpage>357</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Michel1">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Michel</surname><given-names>ML</given-names></name><name name-style="western"><surname>Keller</surname><given-names>AC</given-names></name><name name-style="western"><surname>Paget</surname><given-names>C</given-names></name><name name-style="western"><surname>Fujio</surname><given-names>M</given-names></name><name name-style="western"><surname>Trottein</surname><given-names>F</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia.</article-title>             <source>J Exp Med</source>             <volume>204</volume>             <fpage>995</fpage>             <lpage>1001</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Ivanov1">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ivanov</surname><given-names>II</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>BS</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Tadokoro</surname><given-names>CE</given-names></name><name name-style="western"><surname>Lepelley</surname><given-names>A</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.</article-title>             <source>Cell</source>             <volume>126</volume>             <fpage>1121</fpage>             <lpage>1133</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Crossgrove1">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Crossgrove</surname><given-names>K</given-names></name><name name-style="western"><surname>Maina</surname><given-names>CV</given-names></name><name name-style="western"><surname>Robinson-Rechavi</surname><given-names>M</given-names></name><name name-style="western"><surname>Lochner</surname><given-names>MC</given-names></name></person-group>             <year>2008</year>             <article-title>Orthologues of the Drosophila melanogaster E75 molting control gene in the filarial parasites Brugia malayi and Dirofilaria immitis.</article-title>             <source>Mol Biochem Parasitol</source>             <volume>157</volume>             <fpage>92</fpage>             <lpage>97</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Michel2">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Michel</surname><given-names>ML</given-names></name><name name-style="western"><surname>Mendes-da-Cruz</surname><given-names>D</given-names></name><name name-style="western"><surname>Keller</surname><given-names>AC</given-names></name><name name-style="western"><surname>Lochner</surname><given-names>M</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>E</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Critical role of ROR-gammat in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>105</volume>             <fpage>19845</fpage>             <lpage>19850</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Bonniaud1">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bonniaud</surname><given-names>P</given-names></name><name name-style="western"><surname>Margetts</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Ask</surname><given-names>K</given-names></name><name name-style="western"><surname>Flanders</surname><given-names>K</given-names></name><name name-style="western"><surname>Gauldie</surname><given-names>J</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis.</article-title>             <source>J Immunol</source>             <volume>175</volume>             <fpage>5390</fpage>             <lpage>5395</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Glaccum1">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Glaccum</surname><given-names>MB</given-names></name><name name-style="western"><surname>Stocking</surname><given-names>KL</given-names></name><name name-style="western"><surname>Charrier</surname><given-names>K</given-names></name><name name-style="western"><surname>Smith</surname><given-names>JL</given-names></name><name name-style="western"><surname>Willis</surname><given-names>CR</given-names></name><etal/></person-group>             <year>1997</year>             <article-title>Phenotypic and functional characterization of mice that lack the type I receptor for IL-1.</article-title>             <source>J Immunol</source>             <volume>159</volume>             <fpage>3364</fpage>             <lpage>3371</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Ghilardi1">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ghilardi</surname><given-names>N</given-names></name><name name-style="western"><surname>Kljavin</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>S</given-names></name><name name-style="western"><surname>Gurney</surname><given-names>AL</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice.</article-title>             <source>J Immunol</source>             <volume>172</volume>             <fpage>2827</fpage>             <lpage>2833</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Ye1">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>P</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>FH</given-names></name><name name-style="western"><surname>Kanaly</surname><given-names>S</given-names></name><name name-style="western"><surname>Stocking</surname><given-names>KL</given-names></name><name name-style="western"><surname>Schurr</surname><given-names>J</given-names></name><etal/></person-group>             <year>2001</year>             <article-title>Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense.</article-title>             <source>J Exp Med</source>             <volume>194</volume>             <fpage>519</fpage>             <lpage>527</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Sparwasser1">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sparwasser</surname><given-names>T</given-names></name><name name-style="western"><surname>Gong</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>JY</given-names></name><name name-style="western"><surname>Eberl</surname><given-names>G</given-names></name></person-group>             <year>2004</year>             <article-title>General method for the modification of different BAC types and the rapid generation of BAC transgenic mice.</article-title>             <source>Genesis</source>             <volume>38</volume>             <fpage>39</fpage>             <lpage>50</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Suga1">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Suga</surname><given-names>M</given-names></name><name name-style="western"><surname>Iyonaga</surname><given-names>K</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Gushima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Miyakawa</surname><given-names>H</given-names></name><etal/></person-group>             <year>2000</year>             <article-title>Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias.</article-title>             <source>Am J Respir Crit Care Med</source>             <volume>162</volume>             <fpage>1949</fpage>             <lpage>1956</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Nakae2">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Nakae</surname><given-names>S</given-names></name><name name-style="western"><surname>Nambu</surname><given-names>A</given-names></name><name name-style="western"><surname>Sudo</surname><given-names>K</given-names></name><name name-style="western"><surname>Iwakura</surname><given-names>Y</given-names></name></person-group>             <year>2003</year>             <article-title>Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice.</article-title>             <source>J Immunol</source>             <volume>171</volume>             <fpage>6173</fpage>             <lpage>6177</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Koenders1">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Koenders</surname><given-names>MI</given-names></name><name name-style="western"><surname>Devesa</surname><given-names>I</given-names></name><name name-style="western"><surname>Marijnissen</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Abdollahi-Roodsaz</surname><given-names>S</given-names></name><name name-style="western"><surname>Boots</surname><given-names>AM</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice.</article-title>             <source>Arthritis Rheum</source>             <volume>58</volume>             <fpage>3461</fpage>             <lpage>3470</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Joosten1">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Joosten</surname><given-names>LA</given-names></name><name name-style="western"><surname>Abdollahi-Roodsaz</surname><given-names>S</given-names></name><name name-style="western"><surname>Heuvelmans-Jacobs</surname><given-names>M</given-names></name><name name-style="western"><surname>Helsen</surname><given-names>MM</given-names></name><name name-style="western"><surname>van den Bersselaar</surname><given-names>LA</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1beta and interleukin-17.</article-title>             <source>Arthritis Rheum</source>             <volume>58</volume>             <fpage>98</fpage>             <lpage>108</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Kawanokuchi1">
        <label>35</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kawanokuchi</surname><given-names>J</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>K</given-names></name><name name-style="western"><surname>Nitta</surname><given-names>A</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K</given-names></name><name name-style="western"><surname>Mizuno</surname><given-names>T</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Production and functions of IL-17 in microglia.</article-title>             <source>J Neuroimmunol</source>             <volume>194</volume>             <fpage>54</fpage>             <lpage>61</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Shainheit1">
        <label>36</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Shainheit</surname><given-names>MG</given-names></name><name name-style="western"><surname>Smith</surname><given-names>PM</given-names></name><name name-style="western"><surname>Bazzone</surname><given-names>LE</given-names></name><name name-style="western"><surname>Wang</surname><given-names>AC</given-names></name><name name-style="western"><surname>Rutitzky</surname><given-names>LI</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Dendritic cell IL-23 and IL-1 production in response to schistosome eggs induces Th17 cells in a mouse strain prone to severe immunopathology.</article-title>             <source>J Immunol</source>             <volume>181</volume>             <fpage>8559</fpage>             <lpage>8567</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Ishigame1">
        <label>37</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ishigame</surname><given-names>H</given-names></name><name name-style="western"><surname>Kakuta</surname><given-names>S</given-names></name><name name-style="western"><surname>Nagai</surname><given-names>T</given-names></name><name name-style="western"><surname>Kadoki</surname><given-names>M</given-names></name><name name-style="western"><surname>Nambu</surname><given-names>A</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses.</article-title>             <source>Immunity</source>             <volume>30</volume>             <fpage>108</fpage>             <lpage>119</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Yang1">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>XO</given-names></name><name name-style="western"><surname>Chang</surname><given-names>SH</given-names></name><name name-style="western"><surname>Park</surname><given-names>H</given-names></name><name name-style="western"><surname>Nurieva</surname><given-names>R</given-names></name><name name-style="western"><surname>Shah</surname><given-names>B</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Regulation of inflammatory responses by IL-17F.</article-title>             <source>J Exp Med</source>             <volume>205</volume>             <fpage>1063</fpage>             <lpage>1075</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Shibata1">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Shibata</surname><given-names>K</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>H</given-names></name><name name-style="western"><surname>Hara</surname><given-names>H</given-names></name><name name-style="western"><surname>Kishihara</surname><given-names>K</given-names></name><name name-style="western"><surname>Yoshikai</surname><given-names>Y</given-names></name></person-group>             <year>2007</year>             <article-title>Resident Vdelta1+ gammadelta T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production.</article-title>             <source>J Immunol</source>             <volume>178</volume>             <fpage>4466</fpage>             <lpage>4472</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Jameson1">
        <label>40</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Jameson</surname><given-names>J</given-names></name><name name-style="western"><surname>Havran</surname><given-names>WL</given-names></name></person-group>             <year>2007</year>             <article-title>Skin gammadelta T-cell functions in homeostasis and wound healing.</article-title>             <source>Immunol Rev</source>             <volume>215</volume>             <fpage>114</fpage>             <lpage>122</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Pons1">
        <label>41</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pons</surname><given-names>J</given-names></name><name name-style="western"><surname>Sauleda</surname><given-names>J</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>JM</given-names></name><name name-style="western"><surname>Barcelo</surname><given-names>B</given-names></name><name name-style="western"><surname>Fuster</surname><given-names>A</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Blunted gamma delta T-lymphocyte response in chronic obstructive pulmonary disease.</article-title>             <source>Eur Respir J</source>             <volume>25</volume>             <fpage>441</fpage>             <lpage>446</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Ito1">
        <label>42</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>Y</given-names></name><name name-style="western"><surname>Usui</surname><given-names>T</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>S</given-names></name><name name-style="western"><surname>Iguchi-Hashimoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Ito</surname><given-names>H</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis.</article-title>             <source>Arthritis Rheum</source>             <volume>60</volume>             <fpage>2294</fpage>             <lpage>2303</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Shichita1">
        <label>43</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Shichita</surname><given-names>T</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ooboshi</surname><given-names>H</given-names></name><name name-style="western"><surname>Sugimori</surname><given-names>H</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>R</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury.</article-title>             <source>Nat Med</source>             <volume>15</volume>             <fpage>946</fpage>             <lpage>950</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Huaux1">
        <label>44</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Huaux</surname><given-names>F</given-names></name><name name-style="western"><surname>Arras</surname><given-names>M</given-names></name><name name-style="western"><surname>Tomasi</surname><given-names>D</given-names></name><name name-style="western"><surname>Barbarin</surname><given-names>V</given-names></name><name name-style="western"><surname>Delos</surname><given-names>M</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>A profibrotic function of IL-12p40 in experimental pulmonary fibrosis.</article-title>             <source>J Immunol</source>             <volume>169</volume>             <fpage>2653</fpage>             <lpage>2661</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Komura1">
        <label>45</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Komura</surname><given-names>K</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>F</given-names></name><name name-style="western"><surname>Hara</surname><given-names>T</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Increased serum interleukin 23 in patients with systemic sclerosis.</article-title>             <source>J Rheumatol</source>             <volume>35</volume>             <fpage>120</fpage>             <lpage>125</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Martin1">
        <label>46</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>B</given-names></name><name name-style="western"><surname>Hirota</surname><given-names>K</given-names></name><name name-style="western"><surname>Cua</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Stockinger</surname><given-names>B</given-names></name><name name-style="western"><surname>Veldhoen</surname><given-names>M</given-names></name></person-group>             <year>2009</year>             <article-title>Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals.</article-title>             <source>Immunity</source>             <volume>31</volume>             <fpage>321</fpage>             <lpage>330</lpage>          </element-citation>
      </ref>
      <ref id="pone.0023185-Sonnenberg1">
        <label>47</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sonnenberg</surname><given-names>GF</given-names></name><name name-style="western"><surname>Nair</surname><given-names>MG</given-names></name><name name-style="western"><surname>Kirn</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Zaph</surname><given-names>C</given-names></name><name name-style="western"><surname>Fouser</surname><given-names>LA</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A.</article-title>             <source>J Exp Med</source>             <volume>207</volume>             <issue>6</issue>             <fpage>1293</fpage>             <lpage>1305</lpage>          </element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>